Randomized, prospective trial of two schedules of sorafenib 800 mg daily and interferon alpha in metastatic renal cell carcinoma MRCC a GOIRC phase II study.

Trial Profile

Randomized, prospective trial of two schedules of sorafenib 800 mg daily and interferon alpha in metastatic renal cell carcinoma MRCC a GOIRC phase II study.

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Apr 2013

At a glance

  • Drugs Interferon alpha (Primary) ; Sorafenib (Primary)
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Acronyms RAPSODY
  • Most Recent Events

    • 05 Apr 2013 Status changed from not stated to completed.
    • 23 May 2011 Last checked against European Clinical Trials record.
    • 05 Nov 2010 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top